August 11, 2025 — Legend Biotech Corporation (NASDAQ: LEGN) reported its second quarter 2025 financial results, highlighting CARVYKTI® net trade sales of approximately $439 million. The CARTITUDE-1 study demonstrated positive long-term outcomes, with one-third of patients remaining progression-free for ≥5 years. Over 7,500 patients have been treated to date. The company’s cash and cash equivalents, and time deposits totaled $1.0 billion as of June 30, 2025.
According to Ying Huang, Ph.D., CEO of Legend Biotech, the five-year survival data from CARTITUDE-1 reinforces CARVYKTI’s durability. The FDA also removed Risk Evaluation and Mitigation Strategies (REMS) for approved BCMA- and CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies, including CARVYKTI, and updated product labeling to reduce certain monitoring requirements.
The company presented data at the 2025 ASCO Annual Meeting, including long-term outcomes from the CARTITUDE-1 study and Phase 3 CARTITUDE-4 study subgroup analyses. Preliminary results were announced from Phase 1 studies of LB2102 and LB1908, targeting DLL3 and Claudin 18.2, respectively.
At the EHA 2025 Congress, Legend Biotech presented an analysis of 355 patients from the CARTITUDE program, showing an association between Absolute Lymphocyte Count (ALC) and neurocognitive treatment-emergent adverse events.
Second quarter financial results included license revenue of $35.3 million and collaboration revenue of $219.7 million. The company reported an adjusted net income of $10.1 million for the quarter.
Legend Biotech will host its quarterly earnings call and webcast today at 8:00 am ET.
Jessie Yeung, Investor Contact, Tel: (732) 956-8271, jessie.yeung@legendbiotech.com; Mary Ann Ondish, Press Contact, Tel: (914) 552-4625, media@legendbiotech.com
Source: Legend Biotech
